RATIONALE: Chronically inflamed airways in asthma and chronic obstructive pulmonary disease (COPD) are susceptible to heightened neutrophilic inflammation but the underlying mechanisms are unclear. We previously showed that SP-D deficiency is associated with increased and prolonged neutrophilic inflammation of the airways in mice. Extracellular release of double stranded DNA by neutrophils contributes to the inflammatory injury. We hypothesized that SP-D interferes with this process. METHODS: To study the role of SP-D in airway neutrophilia we exposed wild-type and SP-D-/-mice to ozone (3 ppm, 2 hours) and studied the cellular and molecular inflammatory changes. Bronchoalveolar lavage (BAL) SP-D was investigated by the biotin switch assay and Western blot. Mouse and human neutrophils were studied in vitro for SP-D binding and DNA release by immunochemistry and PicoGreen fluorescence quantitation. RESULTS: SP-D-/-mice had increased myeloperoxidase gene and protein expression in the lung suggesting presence of activated neutrophils. In the BAL of O 3 exposed mice neutrophilic airway inflammation was associated with de-oligomerisation and cysteine nitrosylation of the SP-D molecule. Using recombinant SP-D and confocal imaging, we found that SP-D directly bound to the membrane and inhibited neutrophil extracellular DNA trap formation by human and murine neutrophils in a concentration and carbohydrate-dependent manner. In vitro S-nitrosylation of the recombinant protein abolished the ability of SP-D to block extracellular DNA trap release. CONCLUSIONS: SP-D inhibits extracellular DNA release by neutrophils. An oxidative lung tissue environment damages the SP-D molecule and impairs its immune-protective action leading to exacerbation of airway inflammation.
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Report on Understanding the National Allergy Bureau as a Public Health Surveillance System Audrey F. Pennington, PhD, MPH, Kanta D. Sircar, PhD, and Joy Hsu, MD; Centers for Disease Control and Prevention, Atlanta, GA. RATIONALE: Public health surveillance includes the regular collection and use of data, such as aeroallergen data, to control disease. A standardized framework to describe public health surveillance systems exists but has not yet been used for aeroallergen data systems. We applied this framework to understand the National Allergy Bureau (NAB) as a public health surveillance system. METHODS: We reviewed resources related to the NAB and aeroallergen sampling, visited an NAB station, and interviewed 12 NAB stakeholders. Stakeholders included NAB personnel, NAB station heads, NAB data users, and federal and state public health officials. Collected information was used to assess whether the NAB meets 10 attributes of a public health surveillance system. RESULTS: The NAB meets all 10 attributes to varying degrees. For example, aeroallergen data collected by NAB stations are of high quality due to the rigorous training completed by NAB-certified aeroallergen counters. The NAB makes collected data available to the public within minutes of receiving data from NAB stations, providing real time information on aeroallergen levels and trends. There are currently NAB stations in 32 U.S. states. NAB stations aim to sample at least 3 days a week, but sampling frequency varies between stations. CONCLUSIONS: From this first application of a standardized surveillance framework to the NAB, we found that the NAB excels in the quality, usefulness, and timeliness of its data. By increasing sampling frequency and number of aeroallergen sampling stations, the NAB has the opportunity to increase its representativeness and subsequent public health impact.
